{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:29:17Z","timestamp":1788791357634,"version":"build-2803163510"},"reference-count":61,"publisher":"Rockefeller University Press","issue":"10","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministry of Science, Innovation and Universities","doi-asserted-by":"publisher","award":["PID2023-147515OB-I00"],"award-info":[{"award-number":["PID2023-147515OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["AC22\/00026"],"award-info":[{"award-number":["AC22\/00026"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP22\/00054"],"award-info":[{"award-number":["PMP22\/00054"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"European Union - NextGenerationEU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["TRNSC213881MELE"],"award-info":[{"award-number":["TRNSC213881MELE"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"\u201cLa Caixa\u201d Foundation","doi-asserted-by":"publisher","award":["LCF\/PR\/HR21\/00083"],"award-info":[{"award-number":["LCF\/PR\/HR21\/00083"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101142365"],"award-info":[{"award-number":["101142365"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018779","name":"FERO Foundation","doi-asserted-by":"publisher","award":["BBASELGAFERO2022-01"],"award-info":[{"award-number":["BBASELGAFERO2022-01"]}],"id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000769","name":"University of Oxford","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:p>TNF\u03b1 is a proinflammatory cytokine that can mediate immunosuppressive effects in cancer. Tumors in which we silenced TNFR1 by CRISPR\/Cas9 showed that TNFR1KO variants poorly engrafted in immunocompetent hosts, while engraftment in immunodeficient or CD8 T lymphocyte\u2013depleted mice was preserved. The mechanism was mediated by secondary chemotactic inflammatory mediators elicited by TNF\u03b1 in the malignant cells themselves. As a result, TNFR1KO variants recruited drastically fewer myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment, thus explaining the immune escape of the WT variants. Interestingly, small amounts of TNFR1-sufficient tumor cells co-engrafted with the TNFR1KO variants rescued tumorigenicity in the same tumor lesion but not in distantly implanted TNFR1KO tumors. Secondary mediators chiefly include CXCR1\/2-acting chemokines, prostaglandin E2 and TNF\u03b1 itself. Knocking down TNFR1 in a human tumor cell line rendered comparable MDSC-recruiting results when xenografted. Analyses of scRNA-seq and spatial transcriptomics datasets from human solid tumors corroborate the role of TNFR1 on tumor cells in the induction of secondary pro-tumor inflammatory mediators.<\/jats:p>","DOI":"10.1084\/jem.20252080","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:20:45Z","timestamp":1785910845000},"update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment"],"prefix":"10.1084","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3780-9244","authenticated-orcid":true,"given":"Elixabet","family":"Bola\u00f1os","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6211-6622","authenticated-orcid":true,"given":"Lorena","family":"Ca\u00f1as-Zabala","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5594-2343","authenticated-orcid":true,"given":"Irene","family":"Olivera","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5327-4449","authenticated-orcid":true,"given":"David","family":"Ruiz Guillam\u00f3n","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1594-9898","authenticated-orcid":true,"given":"Enric","family":"Vercher","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-3328","authenticated-orcid":true,"given":"Gabriel","family":"Gomis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7628-8050","authenticated-orcid":true,"given":"Carlos E.","family":"de Andrea","sequence":"additional","affiliation":[{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]},{"id":[{"id":"https:\/\/ror.org\/03phm3r45","id-type":"ROR","asserted-by":"publisher"}],"name":"Clinica Universidad de Navarra, Cancer Center Clinica Universidad de Navarra (CCUN), University of Navarra 3 Department of Pathology, Anatomy and Physiology, , Pamplona,","place":["Spain"]},{"id":[{"id":"https:\/\/ror.org\/03phm3r45","id-type":"ROR","asserted-by":"publisher"}],"name":"Clinica University of Navarra, Cancer Center Cl\u00ednica Universidad de Navarra (CCUN) 4 Department of Immunology and Immunotherapy, , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1903-5636","authenticated-orcid":true,"given":"Raluca","family":"Alexandru","sequence":"additional","affiliation":[{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]},{"id":[{"id":"https:\/\/ror.org\/03phm3r45","id-type":"ROR","asserted-by":"publisher"}],"name":"Clinica Universidad de Navarra, Cancer Center Clinica Universidad de Navarra (CCUN), University of Navarra 3 Department of Pathology, Anatomy and Physiology, , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8511-6050","authenticated-orcid":true,"given":"Arantza","family":"Azpilikueta","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4205-6857","authenticated-orcid":true,"given":"Nekane","family":"Soria","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4396-7127","authenticated-orcid":true,"given":"Dayanna","family":"Salinas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5679-8296","authenticated-orcid":true,"given":"Paula","family":"Molero-Glez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6476-0998","authenticated-orcid":true,"given":"Carlos","family":"Luri-Rey","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5294-1338","authenticated-orcid":true,"given":"Saioa","family":"Arrieta-Aranzueque","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1860-0836","authenticated-orcid":true,"given":"Almudena","family":"Manzanal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4263-7363","authenticated-orcid":true,"given":"Mario","family":"Garcia-Dominguez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"id":[{"id":"https:\/\/ror.org\/04hya7017","id-type":"ROR","asserted-by":"publisher"}],"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC) 5 , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-1375","authenticated-orcid":true,"given":"Diego","family":"Alignani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]},{"id":[{"id":"https:\/\/ror.org\/04hya7017","id-type":"ROR","asserted-by":"publisher"}],"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC) 5 , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6119-1889","authenticated-orcid":true,"given":"Bruno","family":"S\u00e9gui","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ahyrz84","id-type":"ROR","asserted-by":"publisher"}],"name":"Unit\u00e9 Mixte de Recherche INSERM 1037, CNRS 5071, Universit\u00e9 Toulouse III-Paul Sabatier, Centre de Recherches en Canc\u00e9rologie de Toulouse (CRCT) 6 , Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8572-642X","authenticated-orcid":true,"given":"Angie","family":"Molina","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7339-4464","authenticated-orcid":true,"given":"\u00c1lvaro","family":"Teijeira","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]},{"id":[{"id":"https:\/\/ror.org\/04hya7017","id-type":"ROR","asserted-by":"publisher"}],"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC) 5 , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7410-1865","authenticated-orcid":true,"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]},{"id":[{"id":"https:\/\/ror.org\/04hya7017","id-type":"ROR","asserted-by":"publisher"}],"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC) 5 , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":true,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qew8q20","id-type":"ROR","asserted-by":"publisher"}],"name":"Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Cancer Center, Cl\u00ednica Universidad de Navarra (CCUN) 1 , Pamplona,","place":["Spain"]},{"name":"Navarra Institute for Health Research (IDISNA) 2 , Pamplona,","place":["Spain"]},{"id":[{"id":"https:\/\/ror.org\/03phm3r45","id-type":"ROR","asserted-by":"publisher"}],"name":"Clinica University of Navarra, Cancer Center Cl\u00ednica Universidad de Navarra (CCUN) 4 Department of Immunology and Immunotherapy, , Pamplona,","place":["Spain"]},{"id":[{"id":"https:\/\/ror.org\/04hya7017","id-type":"ROR","asserted-by":"publisher"}],"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC) 5 , Madrid,","place":["Spain"]},{"id":[{"id":"https:\/\/ror.org\/052gg0110","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Oxford 7 Nuffield Department of Medicine (NDM), , Oxford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026090709533640200_bib1","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1038\/s41379-020-0600-6","article-title":"Diverse immune environments in human lung tuberculosis granulomas assessed by quantitative multiplexed immunofluorescence","volume":"33","author":"Abengozar-Muela","year":"2020","journal-title":"Mod. Pathol."},{"key":"2026090709533640200_bib2","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41577-024-01062-0","article-title":"Defining myeloid-derived suppressor cells","volume":"24","author":"Akkari","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"2026090709533640200_bib3","doi-asserted-by":"publisher","first-page":"101696","DOI":"10.1016\/j.xcrm.2024.101696","article-title":"TNFR1 signaling promotes pancreatic tumor growth by limiting dendritic cell number and function","volume":"5","author":"Alam","year":"2024","journal-title":"Cell Rep. Med."},{"key":"2026090709533640200_bib4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ctrv.2017.08.004","article-title":"Interleukin-8 in cancer pathogenesis, treatment and follow-up","volume":"60","author":"Alfaro","year":"2017","journal-title":"Cancer Treat Rev."},{"key":"2026090709533640200_bib5","doi-asserted-by":"publisher","first-page":"102409","DOI":"10.1016\/j.coi.2023.102409","article-title":"Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment","volume":"86","author":"Alim","year":"2024","journal-title":"Curr. Opin. Immunol."},{"key":"2026090709533640200_bib6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"2026090709533640200_bib7","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.2217\/fon.10.155","article-title":"TNF: A tumor-suppressing factor or a tumor-promoting factor?","volume":"6","author":"Balkwill","year":"2010","journal-title":"Future Oncol."},{"key":"2026090709533640200_bib8","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/s0140-6736(87)91850-2","article-title":"Evidence for tumour necrosis factor\/cachectin production in cancer","volume":"2","author":"Balkwill","year":"1987","journal-title":"Lancet"},{"key":"2026090709533640200_bib9","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1158\/1078-0432.CCR-20-4084","article-title":"Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)","volume":"27","author":"Bertino","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2026090709533640200_bib10","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"key":"2026090709533640200_bib11","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1158\/0008-5472.CAN-14-2524","article-title":"Blocking tumor necrosis factor \u03b1 enhances CD8 T-cell-dependent immunity in experimental melanoma","volume":"75","author":"Bertrand","year":"2015","journal-title":"Cancer Res."},{"key":"2026090709533640200_bib12","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","article-title":"Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade","volume":"53","author":"Bonavita","year":"2020","journal-title":"Immunity"},{"key":"2026090709533640200_bib13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nri3834","article-title":"Regulation of tumour necrosis factor signalling: live or let die","volume":"15","author":"Brenner","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"2026090709533640200_bib14","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"2026090709533640200_bib15","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2026090709533640200_bib16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41584-021-00584-4","article-title":"TNF in the era of immune checkpoint inhibitors: Friend or foe?","volume":"17","author":"Chen","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"2026090709533640200_bib17","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1200\/JCO.1996.14.10.2653","article-title":"Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial","volume":"14","author":"Eggermont","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"2026090709533640200_bib18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"2026090709533640200_bib19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/ncponc0426","article-title":"Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities","volume":"3","author":"Gr\u00fcnhagen","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"2026090709533640200_bib20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"2026090709533640200_bib21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1158\/1078-0432.CCR-21-1888","article-title":"Therapeutic targeting of LIF overcomes macrophage-mediated immunosuppression of the local tumor microenvironment","volume":"29","author":"Hallett","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"2026090709533640200_bib22","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"2026090709533640200_bib23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0092-8674(95)90070-5","article-title":"The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation","volume":"81","author":"Hsu","year":"1995","journal-title":"Cell"},{"key":"2026090709533640200_bib24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.annonc.2025.10.1239","article-title":"Intratumoral heterogeneity and immunotherapy resistance: Clinical implications","volume":"37","author":"Keenan","year":"2026","journal-title":"Ann. Oncol."},{"key":"2026090709533640200_bib25","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41588-020-0636-z","article-title":"Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer","volume":"52","author":"Lee","year":"2020","journal-title":"Nat. Genet."},{"key":"2026090709533640200_bib26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/path.6012","article-title":"The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients","volume":"258","author":"L\u00f3pez-Janeiro","year":"2022","journal-title":"J. Pathol."},{"key":"2026090709533640200_bib27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41568-024-00785-5","article-title":"Cross-priming in cancer immunology and immunotherapy","volume":"25","author":"Luri-Rey","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"2026090709533640200_bib28","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1158\/1078-0432.CCR-04-0730","article-title":"A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer","volume":"10","author":"Madhusudan","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"2026090709533640200_bib29","doi-asserted-by":"publisher","first-page":"5950","DOI":"10.1200\/JCO.2005.04.127","article-title":"Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer","volume":"23","author":"Madhusudan","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"2026090709533640200_bib30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/imr.12614","article-title":"IL-1 and IL-1 regulatory pathways in cancer progression and therapy","volume":"281","author":"Mantovani","year":"2018","journal-title":"Immunol. Rev."},{"key":"2026090709533640200_bib31","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/s0899-9007(97)00185-8","article-title":"Cytokines and cachexia","volume":"13","author":"Matthys","year":"1997","journal-title":"Nutrition"},{"key":"2026090709533640200_bib32","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/sj.gt.3301957","article-title":"Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFN\u03b3-induced apoptosis","volume":"10","author":"Mazzolini","year":"2003","journal-title":"Gene Ther."},{"key":"2026090709533640200_bib33","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3389\/fimmu.2019.01818","article-title":"The TNF paradox in cancer progression and immunotherapy","volume":"10","author":"Montfort","year":"2019","journal-title":"Front. Immunol."},{"key":"2026090709533640200_bib34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","article-title":"Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: First results of a phase Ib clinical trial","volume":"27","author":"Montfort","year":"2021","journal-title":"Clin Cancer Res."},{"key":"2026090709533640200_bib35","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1172\/JCI116446","article-title":"Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression","volume":"91","author":"Naylor","year":"1993","journal-title":"J. Clin. Invest."},{"key":"2026090709533640200_bib36","doi-asserted-by":"publisher","first-page":"101009","DOI":"10.1016\/j.xcrm.2023.101009","article-title":"Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma","volume":"4","author":"Ochoa","year":"2023","journal-title":"Cell Rep. Med."},{"key":"2026090709533640200_bib37","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1158\/1078-0432.CCR-22-3653","article-title":"Facts and hopes on neutralization of protumor inflammatory mediators in cancer immunotherapy","volume":"29","author":"Olivera","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"2026090709533640200_bib38","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1158\/2159-8290.CD-21-1115","article-title":"A therapeutically actionable protumoral Axis of cytokines involving IL-8, TNF\u03b1, and IL-1\u03b2","volume":"12","author":"Olivera","year":"2022","journal-title":"Cancer Discov."},{"key":"2026090709533640200_bib39","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.7150\/thno.41646","article-title":"Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death","volume":"10","author":"Otano","year":"2020","journal-title":"Theranostics"},{"key":"2026090709533640200_bib40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"2026090709533640200_bib41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026090709533640200_bib42","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"2026090709533640200_bib43","first-page":"447","article-title":"Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro","volume":"138","author":"Robaye","year":"1991","journal-title":"Am. J. Pathol."},{"key":"2026090709533640200_bib44","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma","volume":"9","author":"Ruiz de Galarreta","year":"2019","journal-title":"Cancer Discov."},{"key":"2026090709533640200_bib45","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat. Med."},{"key":"2026090709533640200_bib46","first-page":"445","article-title":"An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors","volume":"2","author":"Scott","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"2026090709533640200_bib47","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1073\/pnas.84.18.6563","article-title":"Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line","volume":"84","author":"Spriggs","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2026090709533640200_bib48","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0002-9440(10)64986-3","article-title":"Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature","volume":"156","author":"Stoelcker","year":"2000","journal-title":"Am. J. Pathol."},{"key":"2026090709533640200_bib49","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41586-023-05704-6","article-title":"Targeting TBK1 to overcome resistance to cancer immunotherapy","volume":"615","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"2026090709533640200_bib50","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/0092-8674(93)90464-2","article-title":"A novel domain within the 55 kd TNF receptor signals cell death","volume":"74","author":"Tartaglia","year":"1993","journal-title":"Cell"},{"key":"2026090709533640200_bib51","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","article-title":"CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity","volume":"52","author":"Teijeira","year":"2020","journal-title":"Immunity"},{"key":"2026090709533640200_bib52","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-20-1319","article-title":"IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy","volume":"27","author":"Teijeira","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2026090709533640200_bib53","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1749-6632.1990.tb00173.x","article-title":"Metabolic responses to cachectin\/TNF. A brief review","volume":"587","author":"Tracey","year":"1990","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2026090709533640200_bib54","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1016\/j.immuni.2024.10.013","article-title":"Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint","volume":"57","author":"Tsao","year":"2024","journal-title":"Immunity"},{"key":"2026090709533640200_bib55","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"2026090709533640200_bib56","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41698-023-00488-4","article-title":"Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics","volume":"8","author":"Valdeolivas","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"2026090709533640200_bib57","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/j.1745-7254.2008.00889.x","article-title":"Tumor necrosis factor and cancer, buddies or foes?","volume":"29","author":"Wang","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"2026090709533640200_bib58","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cell.2019.08.032","article-title":"UVB-induced tumor heterogeneity diminishes immune response in melanoma","volume":"179","author":"Wolf","year":"2019","journal-title":"Cell"},{"key":"2026090709533640200_bib59","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat. Genet."},{"key":"2026090709533640200_bib60","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl6173","article-title":"Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity","volume":"385","author":"Wu","year":"2024","journal-title":"Science"},{"key":"2026090709533640200_bib61","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20252080\/2040670\/jem_20252080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20252080\/2040670\/jem_20252080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:53:45Z","timestamp":1788789225000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/223\/10\/e20252080\/283001\/TNFR1-expression-on-cancer-cells-mediates-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20252080","relation":{},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"e20252080"}}